Title

NO和NP方案治療晚期非小細胞肺癌的前瞻隨機研究

Translated Titles

Efficacy of NO Regimen and NP Regimen on Advanced Non-small Cell Lung Cancer: A Prospective Randomized Trial

Authors

高建飛(Jian-Fei Gao);張新華(Xin-Hua Zhang);王軍(Jun Wang);饒智國(Zhi-Guo Rao);朱宇澤(Yu-Ze Zhu);歐武陵(Wu-Ling Ou);章必成(Bi-Cheng Zhang);杜光祖(Guang-Zu Du)

Key Words

肺腫瘤 ; 癌,非小細胞性 ; 草酸鉑 ; 異長春花鹼 ; 順鉑 ; 藥物療法 ; 聯合 ; Lung neoplasms ; Cancer, non-small cell ; Oxaliplatin ; Vinorelbine ; Cisplatin ; Drug therapy, combination

PublicationName

癌症

Volume or Term/Year and Month of Publication

24卷8期(2005 / 08 / 05)

Page #

990 - 993

Content Language

簡體中文

Chinese Abstract

Background & Objective: Oxaliplatin (LOHP) is an effective drug in treatment of non-small cell lung cancer (NSCLC) with mild toxicities to gastrointestinal tract, kidney, and bone marrow. Cisplatin (DDP) plus vinorelbine (NVB) constitute the first-line regimen (NP regimen) for NSCLC. This study was to compare the short-term response, long-term outcome, and adverse events between advanced NSCLC patients received NO regimen (LOHP plus NVB) and NP regimen. Methods: A total of 90 patients with advanced NSCLC were randomized into NO group (58 patients, 25mg/m^2 of NVB, day1 and day8; 130mg/m^2 of LOHP, day1) and NP group (32 patients, 25mg/m^2 of NVB, day1 and day8; 50mg/m^2 of DDP, day2 and day3). The short-term response, long-term outcome, adverse events, and survival status of the 2 groups were observed. Results: The response rates were 33.33% in NO group, and 35.48% in NP group, but no significant difference was detected between the 2 groups (P>0.05). The clinical benefit response rate was significantly higher in NO group than in NP group (80.70% vs. 64.52%, P<0.05). The median time to progression (TTP) was 17 weeks in NO group, and 15 weeks in NP group; the median time of remission was 21 weeks in NO group, and 19 weeks in NP group; the median survival time was 39 weeks in NO group, and 37 weeks in NP group; the 1-year survival rate was 37.93% in NO group, and 31 .25% in NP group. No significant differences were detected between the 2 groups. The incidence rates of phlebitis and grade I-Ⅱ peripheral neuritis were significantly higher in NO group than in NP group (77.59% vs. 50.00%, P<0.01; 43.10% vs. 15.63%, P<0.01). The incidence rate of grade Ⅲ–Ⅳ nausea/vomiting was significantly higher in NP group than in NO group (31.25% vs. 3.45%, P<0.05). Conclusions: The efficacy of NO regimen on advanced NSCLC is similar to that of NP regimen, but the clinical benefit response rate is higher in NO group than in NP group. In short, NO regimen may be recommended as the first-line chemotherapy regimen for advanced NSCLC.

English Abstract

Background & Objective: Oxaliplatin (LOHP) is an effective drug in treatment of non-small cell lung cancer (NSCLC) with mild toxicities to gastrointestinal tract, kidney, and bone marrow. Cisplatin (DDP) plus vinorelbine (NVB) constitute the first-line regimen (NP regimen) for NSCLC. This study was to compare the short-term response, long-term outcome, and adverse events between advanced NSCLC patients received NO regimen (LOHP plus NVB) and NP regimen. Methods: A total of 90 patients with advanced NSCLC were randomized into NO group (58 patients, 25mg/m^2 of NVB, day1 and day8; 130mg/m^2 of LOHP, day1) and NP group (32 patients, 25mg/m^2 of NVB, day1 and day8; 50mg/m^2 of DDP, day2 and day3). The short-term response, long-term outcome, adverse events, and survival status of the 2 groups were observed. Results: The response rates were 33.33% in NO group, and 35.48% in NP group, but no significant difference was detected between the 2 groups (P>0.05). The clinical benefit response rate was significantly higher in NO group than in NP group (80.70% vs. 64.52%, P<0.05). The median time to progression (TTP) was 17 weeks in NO group, and 15 weeks in NP group; the median time of remission was 21 weeks in NO group, and 19 weeks in NP group; the median survival time was 39 weeks in NO group, and 37 weeks in NP group; the 1-year survival rate was 37.93% in NO group, and 31 .25% in NP group. No significant differences were detected between the 2 groups. The incidence rates of phlebitis and grade I-Ⅱ peripheral neuritis were significantly higher in NO group than in NP group (77.59% vs. 50.00%, P<0.01; 43.10% vs. 15.63%, P<0.01). The incidence rate of grade Ⅲ–Ⅳ nausea/vomiting was significantly higher in NP group than in NO group (31.25% vs. 3.45%, P<0.05). Conclusions: The efficacy of NO regimen on advanced NSCLC is similar to that of NP regimen, but the clinical benefit response rate is higher in NO group than in NP group. In short, NO regimen may be recommended as the first-line chemotherapy regimen for advanced NSCLC.

Topic Category 醫藥衛生 > 內科